Literature DB >> 15477545

Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study.

L M L de Lau1, P C L M Giesbergen, M C de Rijk, A Hofman, P J Koudstaal, M M B Breteler.   

Abstract

OBJECTIVE: To investigate the incidence of parkinsonism and Parkinson disease (PD) in the general population using in-person screening along with clinical data.
METHODS: In the Rotterdam study, a prospective population-based cohort study of people aged > or =55 years, the authors assessed age- and sex-specific incidence rates of parkinsonism and PD among 6,839 participants who were free of parkinsonism at baseline. Case finding involved in-person screening at baseline and two follow-up visits, and additional information was obtained through continuous monitoring of the cohort by computer linkage to general practitioners' and pharmacy records.
RESULTS: After a mean follow-up period of 5.8 years, 132 subjects with incident parkinsonism were identified, of whom 67 (51%) had PD. The incidence of parkinsonism and PD increased with age, with incidence rates for PD increasing from 0.3 per 1000 person-years in subjects aged 55 to 65 years, to 4.4 per 1000 person-years for those aged > or =85 years. The overall age-adjusted incidence rate of any parkinsonism was not different in men and women, but men seem to have a higher risk for PD (male-to-female ratio, 1.54; 95% CI, 0.95 to 2.51).
CONCLUSION: Incidence rates for parkinsonism and Parkinson disease were higher than those reported by most previous studies, possibly because of the authors' intensive case-finding methods involving in-person screening.

Entities:  

Mesh:

Year:  2004        PMID: 15477545     DOI: 10.1212/01.wnl.0000140706.52798.be

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  129 in total

Review 1.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

2.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

3.  Heterogeneity in male to female risk for Parkinson's disease.

Authors:  K S M Taylor; J A Cook; C E Counsell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-08       Impact factor: 10.154

4.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

5.  Changes to Ventilation, Vocalization, and Thermal Nociception in the Pink1-/- Rat Model of Parkinson's Disease.

Authors:  Rebecca A Johnson; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

6.  Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism.

Authors:  P H Lee; J S Kim; D H Shin; S-N Yoon; K Huh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08-15       Impact factor: 10.154

Review 7.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 8.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

9.  Gender differences in cholinergic and dopaminergic deficits in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  J Neural Transm (Vienna)       Date:  2013-03-27       Impact factor: 3.575

Review 10.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.